APOE genotypes as a risk factor for age‐dependent accumulation of cerebrovascular disease in older adults. Issue 2 (12th October 2018)

• Record Type: Journal Article
• Authors: Lamar, Melissa; Yu, Lei; Rubin, Leah H.; James, Bryan D.; Barnes, Lisa L.; Farfel, Jose Marcelo; Gaiteri, Chris; Buchman, Aron S.; Bennett, David A.; Schneider, Julie A.
• Is Part Of: Alzheimer's & dementia. Volume 15:Issue 2(2019)
• Page Start: 258
• Page End: 266
• Publication Date: 2018-10-12
• Subjects: APOE ε4 allele -- APOE ε2 allele -- Cerebrovascular disease -- Neuropathology -- Oldest old; Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1016/j.jalz.2018.08.007
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Introduction: Apolipoprotein E ( APOE ) is a susceptibility gene for late‐onset Alzheimer's disease neuropathology; less is known about the relationship between APOE and cerebrovascular disease (CVD) neuropathology. Methods: We investigated associations of APOE status with arteriolosclerosis, macroinfarcts and microinfarcts, and atherosclerosis in 1383 adults (65.9–108.2 years at death) with and without dementia. Excluding ε2/ε4 carriers, multivariable regressions for each CVD‐related neuropathology compared ε4 and ε2 carriers to ε3/ε3 carriers adjusting for confounders including age and Alzheimer's neuropathology. Results: Three hundred forty‐two individuals (24.7%; ∼87.7 years at death; 39.9% nondemented) were ε3/ε4 or ε4/ε4, and 180 (13.0%; ∼89.9 years at death; 66.6% nondemented) were ε2/ε3 or ε2/ε2. ε4 carriers had higher odds of macroinfarcts (odds ratio = 1.41, 95% confidence interval: 1.02–1.94, P = .03), whereas ε2 carriers had higher odds of moderate‐to‐severe arteriolosclerosis (odds ratio = 1.68, 95% confidence interval: 1.15–2.45, P = .006) compared to ε3/ε3 carriers. Age‐stratified analyses suggested that these relationships were driven by ε4 carriers <90 years at death and ε2 carriers ≥90 years at death, respectively. Discussion: APOE differentially affects type and timing of CVD‐related neuropathology.